Transcode Therapeutics, Inc.
For the period ended Oct 8, 2025. Filed Oct 8, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 8, 2025 · Filed Oct 8, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · About TransCode Therapeutics
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.